[{"orgOrder":0,"company":"Lotte Biologics","sponsor":"PINOTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Sacituzumab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lotte Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Lotte Biologics \/ Lotte Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Lotte Biologics \/ Lotte Biologics"}]

Find Clinical Drug Pipeline Developments & Deals by Lotte Biologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The investment will facilitate the creation of a cross-industry synergistic environment for the development and production of ADC platforms including, PINOT-ADC™, a next-generation ADC anti-cancer drug platform developing PBX-001 (sacituzumab), targeti...

                          Brand Name : PBX-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 21, 2023

                          Lead Product(s) : Sacituzumab Govitecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : PINOTBIO

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank